^
    Back
    Association details:
    Biomarker:KRAS G12A
    Cancer:Non Small Cell Lung Cancer
    Drug Class:Immunotherapy
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Cancer
    Title:

    Real-world retrospective study of KRAS mutations in advanced nonsmall cell lung cancer in the era of immunotherapy

    Published date:
    03/11/2023
    Excerpt:
    The objective of this study was to retrospectively analyze all consecutive patients with advanced/metastatic, KRAS-positive NSCLC who were diagnosed at a single academic institution since the advent of immunotherapy....a numerically lower mOS was observed in patients harboring p.G12D and p.G12A (7.1 and 5.2 months, respectively).
    DOI:
    https://doi.org/10.1002/cncr.34731